KLK5 Antibody

1. persistently upregulated KLK5 resulted in atopic dermatitis-like skin architecture and secretion of atopic dermatitis-related cytokines from keratinocytes in a PAR2 independent manner PMID:28238749
2. It may be considered that circulating kallikrein 5 is down-regulated in chronic spontaneous urticaria patients, however its potential role and the possible underlying mechanism are unknown. PMID:28685545
3. Thus, these findings point to the involvement of KLK5 in the proteolytic activation and spread of seasonal influenza viruses in humans. PMID:28615200
4. The results of the present study indicated that the mRNA and protein expression levels of KLK5 were significantly upregulated in CRC tissues and sera, and were associated with an advanced tumor stage. PMID:27430713
5. the expression level of hK5 in tumor stromal cells is a promising biomarker for poor prognosis in TNBC. PMID:26345898
6. This report demonstrates that concurrent loss of KLK5 and KLK7 associates with a poor clinical outcome in Oral Squamous-Cell Carcinoma and could therefore serve as prognostic marker in this disease. PMID:26022646
7. Low KLK5 expression is associated with breast cancer. PMID:24158494
8. KLK5 is an important contributor to the Netherton syndrome proteolytic cascade. PMID:24534191
9. Data indicate that the KLK5 SNP rs268908 was associated with an increased risk of prostate cancer. PMID:21741862
10. Kallikrein 5 and kallikrein 12 cleave human influenza hemagglutinins and activate thrombolytic zymogens. PMID:23612974
11. KLK5 is required for biochemical processing of profilaggrin in human skin. PMID:23629652
12. the inhibition and binding of different SPINK9 variants towards KLK5, KLK7, KLK8 and KLK14 PMID:22505519
13. Loss of KLK5 is associated with ovarian cancer. PMID:22102857
14. Increased serum and ascitic fluid KLK5 levels are associated with poor patient outcome, thus underlining the importance of KLK5 as a biomarker for early detection as well as for disease management in ovarian cancer. PMID:21273346
15. Significant co-expression of KLKs 5 and 7 was observed in the same cancer samples. Increased KLK5 expression was a statistically significant independent prognostic factor for DFS and OS of patients PMID:21868565
16. KLK5 may promote metastatic dissemination of OSCC by promoting loss of junctional integrity through cleavage of desmoglein 1. PMID:21163944
17. expression and activity of KLK are under fine control and can be distinctly influenced by variables such as differentiation, calcium, vitamin D, and retinoic acid PMID:20090765
18. expression in prostate cancer negatively correlated with cancer aggressiveness PMID:11948967
19. We found significantly lower expression of KLK5 in testicular tumors than in normal testicular tissue. PMID:12385949
20. High expression of KLK5 transcript with a short 5'-untranslated region is associated with ovarian cancer PMID:12738725
21. has trypsin-like substrate specificity and forms complexes with protease inhibitors in serum and ascites fluid from ovarian cancer patients PMID:12890555
22. scte induced degradation of three corneodesmosomal components: corneodesmosin, desmocollin 1 and desmoglein 1 PMID:15140227
23. may be part of a protease cascade in the stratum corneum, and that the observed pH effects may have physiological relevance PMID:15654974
24. hK5 may be implicated in tumor progression, particularly in invasion and angiogenesis PMID:15713679
25. variability in KLK5 and KLK7 gene expression might be involved in lung tumorigenesis PMID:15766562
26. hK5 is able to internally cleave insulin-like growth factor-binding proteins 1, 2, 3, 4, and 5, but not 6, suggesting that it might be involved in prostate cancer progression through growth factor regulation PMID:16517595
27. in majority of patients with Netherton syndrome, Dsg1 & Dsc1 were reduced in living layers of epidermis; SCTE-like & SCCE-like activities were increased, suggesting these proteases participate in premature degradation of corneodesmosomal cadherins PMID:16628198
28. KLK5 and KLK7 were shown to control activation of CAP18 and also influence further processing to smaller peptides with alternate biological activity; the balance of proteolytic activity at an epithelial interface will control innate immune defense PMID:17012259
29. KLK5 may participate in epidermal desquamation through cleavage of desmoglein 1 and regulation by lympho-epithelial Kazal-type-related inhibitor (LEKTI). PMID:17158887
30. A target of gene amplification, which may play a crucial role in promoting cancer-cell invasion in bladder tumor. PMID:17459052
31. KLK5 and KLK14, but neither KLK7 nor KLK8, induced PAR2 signalling. PMID:17625593
32. Dada shoe that the His96-99-57 triad is responsible for the Zn2+-mediated inhibition of hK5 catalysis. PMID:17881000
33. predominant localisation of KLK5 and KLK7 in acinar cells of the exocrine pancreas; KLK5 and KLK7 generate transcripts in pancreas variant from those in skin or ovary PMID:18163887
34. KLK4 and KLK5 activate pro-HGFA. PMID:18221492
35. the KLK region was subject to copy number imbalances or involved in unbalanced translocations and were associated with increased protein expression of KLKs 5, 6, 7, 8, 9, 10 and 11 in ovarian cancer cells PMID:19383346
36. Parallel underexpression of KLK5 and KLK7 mRNA in breast malignancies is reported. PMID:19453546
37. KLK5 is a potential new biomarker to be used in combination with other biomarkers for ovarian cancer detection. PMID:19820362

Show More

Hide All

HGNC: 6366

UNIGENE: Hs.50915

KEGG: hsa:25818

STRING: 9606.ENSP00000337733

OMIM: 605643